Boehringer Says Cephalon Ruling Can't Help Aggrenox Class

By Amber McKinney (February 9, 2015, 8:30 PM EST) -- Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. have hit back at the class plaintiffs in the Aggrenox pay-for-delay litigation, saying the Pennsylvania federal judge's recent ruling denying summary judgment in the Federal Trade Commission's Cephalon case doesn't back the plaintiffs' opposition to the motion to dismiss in this case.

The defendants essentially argue in their brief that the U.S. District Judge Mitchell S. Goldberg of Pennsylvania's Eastern District got the law wrong on who has the burden of proving that a settlement is anti-competitive.

The drugmakers are referring to the ruling issued late last month in King Drug Company of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!